Immunic (Nasdaq:IMUX) - Stock Price, News & Analysis

IMUX Stock Overview

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany.

About the company

IMUX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	3/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings are forecast to grow 57.77% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($0)

Immunic, Inc. Competitors

Vor Biopharma

NasdaqGS:VOR

US$116.0m

Coya Therapeutics

NasdaqCM:COYA

US$123.1m

Genetron Holdings

NasdaqGM:GTH

US$127.3m

Vistagen Therapeutics

NasdaqCM:VTGN

US$127.0m

Price History & Performance

Summary of all time highs, changes and price drops for Immunic
Historical stock prices
Current Share Price	US$1.26
52 Week High	US$3.11
52 Week Low	US$0.95
Beta	1.95
1 Month Change	-1.56%
3 Month Change	10.04%
1 Year Change	-24.10%
3 Year Change	-91.83%
5 Year Change	-89.77%
Change since IPO	-94.78%

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Jan 22

Recent updates

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Jan 22

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Oct 13

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

Jun 27

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Oct 20

Shareholder Returns

	IMUX	US Biotechs	US Market
7D	-0.8%	0.4%	1.0%
1Y	-24.1%	0.9%	21.9%

Return vs Industry: IMUX underperformed the US Biotechs industry which returned 0.7% over the past year.

Return vs Market: IMUX underperformed the US Market which returned 24.9% over the past year.

Price Volatility

Is IMUX's price volatile compared to industry and market?
IMUX volatility
IMUX Average Weekly Movement	9.6%
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	3.0%

Stable Share Price: IMUX has not had significant price volatility in the past 3 months.

Volatility Over Time: IMUX's weekly volatility (10%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2016	77	Daniel Vitt	imux.com

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases.

Immunic, Inc. Fundamentals Summary

How do Immunic's earnings and revenue compare to its market cap?
IMUX fundamental statistics
Market cap	US$113.50m
Earnings (TTM)	-US$93.61m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.2x

P/E Ratio

Is IMUX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMUX income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$93.61m
Earnings	-US$93.61m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-1.04
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did IMUX perform over the long term?

See historical performance and comparison

IMUX Stock Overview

Rewards

Risk Analysis

Immunic, Inc. Competitors

NasdaqGS:VOR

US$116.0m

NasdaqCM:COYA

US$123.1m

NasdaqGM:GTH

US$127.3m

NasdaqCM:VTGN

US$127.0m

Price History & Performance

Recent News & Updates

Immunic, Inc., Annual General Meeting, Jun 11, 2024

Price target decreased by 32% to US$9.00

Immunic, Inc. to Report Fiscal Year 2023 Results on Feb 22, 2024

New major risk - Shareholder dilution

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Immunic, Inc. announced that it expects to receive $240 million in funding from BVF Partners L.P., Avidity Partners, LLC, Janus Henderson Investors, Soleus Capital, RTW Investments, LP, Adage Capital Management, L.P.

Recent updates

Immunic, Inc., Annual General Meeting, Jun 11, 2024

Price target decreased by 32% to US$9.00

Immunic, Inc. to Report Fiscal Year 2023 Results on Feb 22, 2024

New major risk - Shareholder dilution

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Immunic, Inc. announced that it expects to receive $240 million in funding from BVF Partners L.P., Avidity Partners, LLC, Janus Henderson Investors, Soleus Capital, RTW Investments, LP, Adage Capital Management, L.P.

Forecast to breakeven in 2026

New major risk - Financial position

Immunic, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis Vidofludimus and Its Salts

Immunic, Inc. Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Immunic Reports Positive Interim Data from Phase 2 Calliper Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

Immunic, Inc. Completes Enrollment of Its Phase 2 CallIPER Trial ofidofludimus Calcium in Progressive Multiple Sclerosis

New major risk - Share price stability

Immunic, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

Immunic, Inc. to Report Q1, 2023 Results on May 11, 2023

Immunic, Inc. Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

High number of new directors

Price target decreased by 15% to US$18.00

Immunic, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Independent Director recently bought US$103k worth of stock

Immunic, Inc Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential

High number of new directors

Price target decreased to US$21.17

Price target decreased to US$21.17

Immunic, Inc. Provides Impairment Guidance for the Quarter Ending December 31, 2022

Immunic, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Price target increased to US$28.75

Immunic, Inc. Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Immunic, Inc. announced that it expects to receive $59.949037 million in funding from a group of investors

Immunic stock gains on $60M oversubscribed PIPE financing

Immunic, Inc Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects

Immunic, Inc. Receives Notice of Allowance for Composition-Of-Matter Patent in the United States for IMU-856, A Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium

Price target decreased to US$22.40

Immunic GAAP EPS of -$0.72 in-line

Immunic, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Immunic, Inc. Announces Executive Changes

Immunic, Inc.(NasdaqGS:IMUX) dropped from Russell 2000 Dynamic Index

Immunic, Inc. Announces Publication of Data From its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology

Immunic, Inc. Reports Top-Line Data from Phase 2 Caldose-1 Trial of Vidofludimus Calcium in Patients with Moderate-To-Severe Ulcerative Colitis

Price target decreased to US$49.43

Executive Chairman recently bought US$50k worth of stock

Immunic, Inc. Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

Immunic, Inc. to Report Q1, 2022 Results on May 10, 2022

High number of new directors

Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis

Immunic, Inc. to Report Fiscal Year 2021 Results on Feb 24, 2022

Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of Its Phase I Clinical Trial of IMU-935

Immunic, Inc. Announces Enrollment of the First Patient in Its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer

Here's Why We're Watching Immunic's (NASDAQ:IMUX) Cash Burn Situation

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

Immunic, Inc.(NasdaqGS:IMUX) dropped from Russell 2500 Growth Index

Executive Chairman recently bought US$51k worth of stock